

Benzodiazepine Withdrawal Management

These toolkits are derived from the QLD Alcohol and Drug Withdrawal Clinical Practice Guidelines 2012. Medical Addiction specialists will be able to offer additional expert opinion based upon current evidence.



Centre for alcohol and other drug training and workforce development

1 SCREENING

Severity of Dependence SDS Scale

| Record the answer that best represents the consumer's personal feelings towards their benzodiazepine use over the previous twelve months. | | | | |
|---|---------------------------|---------------|-----------|-----------------------------|
| Did you ever think your benzodiazepines use was out of control? | Never or almost never (0) | Sometimes (1) | Often (2) | Always or nearly always (3) |
| Did the prospect of not using benzodiazepines make you anxious or worried? | Never or almost never (0) | Sometimes (1) | Often (2) | Always or nearly always (3) |
| How much did you worry about your use of benzodiazepines? | Never or almost never (0) | Sometimes (1) | Often (2) | Always or nearly always (3) |
| Did you wish you could stop using benzodiazepines? | Never or almost never (0) | Sometimes (1) | Often (2) | Always or nearly always (3) |
| How difficult would you find it to stop or go without benzodiazepines? | Never or almost never (0) | Sometimes (1) | Often (2) | Always or nearly always (3) |
| <i>Benzodiazepines > 7 indicates dependence (Cuevas C, Sanz E, de la Fuente J, Padilla J, Berenguer J. 2000).</i> | | | | Total /15 |

2 ASSESSMENT

Perform Comprehensive Assessment

- Consumption history:** Average daily intake (higher doses increase severity of dependence), frequency of use (number of doses per day?), duration of use - months or years, type of benzodiazepine used (short – or long-acting), history of severity of withdrawal symptoms, means of obtaining the benzodiazepine (prescribed, 'doctor shopping', fraudulently?), other drug use? day/time of last use
Visit QScript to investigate prescribing history (<https://www.qscript.health.qld.gov.au/>)
- Biopsychosocial history:** Medical and psychiatric conditions, social history and collateral relating to presentation
- Investigations:** Bloods (eLFTS, FBC) Urine drug screen, Blood Borne Virus screen
- Physical examination:** Neurological observations, assess for IV use (patency and health of veins - assess for cellulitis/ infected access sites)

3 MONITORING

Convert Diazepam Equivalents

| Generic name | Trade name | Time to peak concentration | Elimination half-life# | Equivalent dose** | |
|---------------|--------------------------------------|---|--|-------------------|--|
| Diazepam | Antenex, Ducene, Valium, Valpam | 30-90 mins | Biphasic: rapid phase half-life 3 hours; elimination half-life 20-48 hours | 5mg | |
| Alprazolam | Alprax, Xanax*, Kalma | 1 hour | 6-25 hours | 0.5-1mg | |
| Clonazepam | Paxam, Rivotril | 2-3 hours | 22-54 hours | 0.5mg | |
| Flunitrazepam | Hypnodorm | 1-2 hours | 20-30 hours | 1-2mg | |
| Lorazepam | Ativan | 2 hours | 12-16 hours | 1mg | |
| Nitrazepam | Alodorm, Mogadon | 2 hours | 16-48 hours | 2.5-5mg | |
| Oxazepam | Alepam, Murelax, Serepax | 2-3 hours | 4-15 hours | 15-30mg | |
| Temazepam | Euphygnos, Normison, Temaze, Temtabs | 30-60 minutes after tablets, 2 hours after capsules | 5-15 hours | 10-20 mg | |
| Zopiclone *** | Imovane | 1.75 hours | 5.5 hours | 7.5mg | (note: not full benzodiazepines, so not directly equivalent) |
| Zolpidem *** | Stilnox | 0.5 -3hours | 2.5 hours | 10mg | |

Based on manufacturer's product information; #elimination half-life: time for plasma concentration to decrease by 50%;*Xanax no longer produced and most likely counterfeit,**Equiv dose approximate to 5mg diazepam, ***Added for information only

Benzodiazepine Withdrawal Scale CIWA-B


- Implement and monitor CIWA-B, using as a guide to monitor withdrawal trends as a compliment to to clinical assessment during dosage reduction
- *Inpatient only- for stabilisation and significant dose reudction: Commence at fourth hourly and reduce as scores settle*
- Use objective data and clinical judgement to guide management

Symptoms

Common: Anxiety; Insomnia; Restlessness; Agitation; Irritability; Poor concentration; Poor memory; Depression; Muscle tension; Aches and twitching; Nightmares; Agoraphobia; Feelings of unreality; Depersonalisation; Panic attacks; Nausea; Dry retching; Decreased appetite; Weight loss; Sweating; Lethargy; Increased sensory perception; Aches and pains; Headaches; Palpitations; Tremor; Blurred vision; Increased temperature; Ataxia; Menstrual changes

Uncommon: Delusions; Paranoia; Hallucinations; Seizures; Persistent tinnitus; Confusion

Course of Withdrawal



Adapted from Frank L, Pead J, (1995). *New Concepts in Drug Withdrawal: a resource handbook*. Victoria. Reproduced with permission.

Reduction regime

Rate of benzodiazepine withdrawal should be individualised and flexible. Rates may need to be slowed further towards the end of tapering

| Example regime - Rapid withdrawal | |
|--|------------------------|
| Daily dose of 40-80mg diazepam | Reduce by 5mg / week |
| Daily dose of < 40mg diazepam | Reduce by 2.5mg / week |
| Example regime - Slow withdrawal | |
| Daily dose of 40-80mg diazepam | Reduce by 10mg / week |
| Daily dose of <40mg diazepam | Reduce by 5mg / week |
| Poly substance use / high doses (<i>inpatient only</i>) | |
| Stabilise on a long-acting benzodiazepine (preferably diazepam), at a dose about 40% of their regular intake before admission (or 80mg/day whichever is lower). Reduction and withdrawal should follow | |

Supportive Pharamcotherapies

| Symptoms | Supportive Pharmacotherapies |
|--|---|
| Sleep Problems | Promethazine |
| Hallucinations Mood disturbances | Olanzapine (low dose e.g. 2.5mg while symptoms persist titrated against symptoms) |
| Stomach pains Physical pain Nausea | Hyoscine butylbromide Paracetamol, NSAIDS Metoclopramide, promethazine |

Psychotherapeutic interventions

Anxiety, sleeping disorders and other concurrent psychological problems are common and must be treated throughout withdrawal regime

| Psychosocial Interventions |
|--|
| <ul style="list-style-type: none"> • Progressive muscle relaxation • Relaxation (app or CD) • Sensory Approaches • Challenging irrational beliefs • Physical activity /exercise • Relaxation strategies, breathing and meditation techniques • CBT and mindfulness approaches • Stress management • Mood management • Coping strategies • Activity scheduling • Timetabling pleasant activities • Anger management • Sleep hygiene • Solution-focused brief therapies (SFBT) • Motivational Interviewing techniques • Decisional balance • Readiness /confidence to change ruler • Psychoeducation • Goal-setting • Nutrition and hydration |

Variances to Standard Withdrawal Protocols

- Do not prescribe benzodiazepines for patients on methadone or buprenorphine programs without consultation with treating physician.
- View QScript record to check whether they are obtaining prescriptions from other doctors
<https://www.qscript.health.qld.gov.au/>
- Consider cross tolerance with alcohol – perform full alcohol and drug assessment
- Caution diazepam use in hepatic/renal dysfunction - Consider oxazepam as alternative.

Alcohol and Drug Clinical Advisory Service: 1800 290 928 08:00 - 23:00 / 7 days (for clinician only)

Post-Withdrawal Treatment Options

| | |
|--------------------|---|
| Relapse Prevention | Adis 24/7 Alcohol and Drug Support 1800 177 833 adis.health.qld.gov.au Individual counselling Self-help groups (AA, NA, Smart Recovery) Residential rehabilitation Family Drug Support (FDS) - 1300 368 186 |
|--------------------|---|